IGFBP-3 Test: When to Order It, What Your Results Mean, and How It Affects Women Across Every Life Stage

What Is IGFBP-3 and Why Does It Matter for Women?

IGFBP-3, or insulin-like growth factor binding protein 3, is the dominant carrier for IGF-1 and IGF-2 in your blood. Think of it as a molecular chaperone: roughly 75 to 90 percent of all circulating IGF-1 is bound to IGFBP-3 in a ternary complex that extends IGF-1's half-life from minutes to hours. When that complex breaks apart, free IGF-1 becomes available to act on tissues.

Because IGFBP-3 is more stable in the bloodstream than IGF-1 alone, it often gives a cleaner signal of long-term growth hormone (GH) axis activity than a single IGF-1 draw. The Endocrine Society clinical practice guideline on growth hormone deficiency recommends IGFBP-3 as a co-marker when evaluating GH axis disorders, particularly in children and in adults where IGF-1 may be borderline.

Why Women Are Not Just "Small Men" Here

GH secretion, IGF-1 production, and IGFBP-3 levels are all sex-hormone dependent. Estrogen influences GH pulse amplitude and hepatic GH receptor sensitivity, which means your results shift across the menstrual cycle, across reproductive life stages, and dramatically at menopause. Male-derived reference ranges used in some older laboratory reports can misclassify a healthy premenopausal woman as having low GH axis activity. Always ask your clinician whether the lab's reference range is stratified by sex and age.

The GH-IGF-1-IGFBP-3 Axis in Plain Language

Your hypothalamus releases GHRH. Your pituitary responds by secreting GH in pulses, mostly at night. The liver converts that GH signal into IGF-1 and simultaneously into IGFBP-3. So a high IGFBP-3 generally means the GH axis is active, and a low IGFBP-3 generally means it is suppressed. Insulin and nutritional status also regulate IGFBP-3 independently of GH, which is why metabolic conditions like PCOS matter.

Normal IGFBP-3 Ranges for Women

Reference ranges vary by laboratory assay and are strongly age-dependent. The numbers below are drawn from published normative data using the Diagnostic Systems Laboratories immunoradiometric assay, one of the most commonly cited datasets in adult endocrinology.

| Age Group | IGFBP-3 Reference Range (mg/L) | |---|---| | 20 to 29 years | 3.4 to 7.8 | | 30 to 39 years | 3.1 to 7.0 | | 40 to 49 years | 2.8 to 6.4 | | 50 to 59 years | 2.4 to 6.0 | | 60 to 69 years | 2.1 to 5.5 | | 70 years and older | 1.7 to 4.8 |

These are population medians, not therapeutic targets. A result at the low end of the range for a 35-year-old is very different clinically from the same absolute number in a 65-year-old.

What Changes the Number Beyond Age

Several factors shift IGFBP-3 that are not part of a GH axis disorder:

• Insulin resistance: High circulating insulin suppresses hepatic IGFBP-3 production, so women with PCOS or type 2 diabetes often have lower-than-expected IGFBP-3 for their age. A 2003 meta-analysis in Fertility and Sterility found IGFBP-3 was significantly reduced in women with PCOS compared with weight-matched controls.
• Liver disease: Because the liver makes IGFBP-3, hepatic dysfunction depresses levels regardless of GH status.
• Thyroid status: Hypothyroidism blunts the GH axis and lowers both IGF-1 and IGFBP-3. Postpartum thyroiditis is a common cause in women ages 20 to 40.
• Nutritional state: Caloric restriction and low protein intake reduce IGFBP-3. Women with eating disorders or severe caloric restriction may show low results that normalize with refeeding.
• Exogenous estrogen: Oral estrogen reduces hepatic IGF-1 and IGFBP-3 production. Transdermal estrogen has a much smaller suppressive effect on this axis.

When Should You Order an IGFBP-3 Test?

Order IGFBP-3 when you need a more stable or complete picture of GH axis function than IGF-1 alone provides. The Endocrine Society and AACE guidelines identify the following primary indications.

Suspected GH Deficiency in Adults

GH deficiency in adults (AGHD) is more common than most clinicians realize. Women, particularly those who experienced pituitary damage from postpartum hemorrhage (Sheehan syndrome) or cranial irradiation, are a high-risk group. Symptoms overlap heavily with perimenopause: fatigue, reduced muscle mass, increased central adiposity, impaired quality of life. That overlap means AGHD is chronically under-recognized in perimenopausal women.

When IGF-1 is borderline low, adding IGFBP-3 strengthens the diagnostic picture. A study published in the Journal of Clinical Endocrinology and Metabolism showed that the combination of low IGF-1 and low IGFBP-3 had higher specificity for confirming AGHD than either marker alone.

Suspected Acromegaly

Acromegaly is caused by excess GH, most often from a pituitary adenoma. Its incidence is approximately 3 to 4 cases per million people per year, but the average delay to diagnosis is 6 to 10 years because symptoms develop gradually. Women may present with menstrual irregularity, amenorrhea, or infertility before the classic features of jaw enlargement and hand growth are obvious. IGFBP-3 is elevated in most active acromegaly cases and can serve as a confirmatory marker alongside IGF-1 and the oral glucose tolerance test for GH suppression.

Monitoring During Acromegaly Treatment

After surgery, radiation, or somatostatin analog therapy, both IGF-1 and IGFBP-3 are tracked to assess biochemical remission. The 2014 Endocrine Society acromegaly guidelines recommend normalizing IGF-1 as the primary biochemical endpoint, with IGFBP-3 used as a supporting marker.

Pediatric Growth Assessment

In children being evaluated for short stature or suspected GH deficiency, IGFBP-3 is more stable than IGF-1 across the wide swings of puberty. The GH Research Society consensus statement supports its use in pediatric GH axis evaluation, especially in younger children where IGF-1 concentrations are normally very low and harder to interpret.

When Not to Order It as a Standalone Test

IGFBP-3 in isolation is not a cancer screening tool. Some observational studies have examined IGFBP-3 in relation to breast cancer risk, but the IARC working group and subsequent analyses found no consistent independent association sufficient to justify routine use as a cancer biomarker. Do not order it solely for cancer risk stratification outside a research context.

What High IGFBP-3 Means

A high IGFBP-3, particularly when paired with a high IGF-1, points toward GH excess. The most common cause is acromegaly. Other causes include:

• Adolescence and puberty (physiologically high; not pathological)
• Pregnancy, especially the second and third trimester
• Obesity with preserved GH sensitivity (paradoxically, some obese patients maintain normal or even high IGFBP-3 while IGF-1 is low, because insulin suppresses IGF-1 more than IGFBP-3)

If your IGFBP-3 comes back elevated and you have symptoms of acromegaly, such as ring size increase, snoring that worsened recently, joint pain, or new skin tags, ask your clinician about an oral glucose tolerance test with GH measurement. An IGF-1 that does not suppress below 1.0 ng/mL during a 75-gram oral glucose tolerance test is the confirmatory criterion for acromegaly per the Endocrine Society.

What Low IGFBP-3 Means

Low IGFBP-3, especially alongside a low IGF-1, suggests reduced GH axis activity. The clinical meaning depends entirely on context.

In Reproductive-Age Women

Low IGFBP-3 in a woman of reproductive age should prompt evaluation for:

• Hypopituitarism (particularly post-pregnancy pituitary damage from Sheehan syndrome)
• Eating disorders or severe caloric restriction
• Uncontrolled hypothyroidism
• Chronic liver disease
• Insulin resistance suppressing IGFBP-3 (PCOS is the most common scenario)

For women with PCOS, a low IGFBP-3 does not mean GH deficiency. It reflects the insulin-mediated suppression of hepatic IGFBP-3 production. A study in the Journal of Clinical Endocrinology and Metabolism showed that treating insulin resistance with metformin in PCOS raised IGFBP-3 toward normal ranges without changing GH secretion itself.

In Perimenopausal and Post-Menopausal Women

Estrogen stimulates GH secretion and maintains IGF-1 and IGFBP-3 levels. As estrogen falls during perimenopause, GH pulse amplitude decreases and both IGF-1 and IGFBP-3 decline. A longitudinal analysis from the Study of Women's Health Across the Nation (SWAN) documented significant reductions in IGF-1 across the menopausal transition, with parallel shifts in IGFBP-3. This means that a IGFBP-3 value that looks low in a post-menopausal woman may be entirely appropriate for her hormonal status, not a sign of pathology.

Oral menopausal hormone therapy suppresses hepatic IGF-1 and IGFBP-3 more than transdermal therapy. If you are on oral estrogen and your clinician is interpreting your IGFBP-3, that route of administration matters significantly.

In Women With GH Deficiency

When GH deficiency is confirmed by stimulation testing, the degree of IGFBP-3 suppression helps guide the starting dose of GH replacement. Women require higher weight-based GH doses than men to achieve the same IGF-1 response, as demonstrated in pharmacokinetic studies reviewed in the AACE GH deficiency guidelines. Women on oral estrogen need even higher GH doses because oral estrogen blunts hepatic IGF-1 and IGFBP-3 production. Switching to transdermal estrogen before starting GH replacement is often a practical first step.

IGFBP-3 Across Women's Life Stages

Reproductive Years (Ages 18 to 40)

IGFBP-3 is at its lifetime peak during the mid-reproductive years. The menstrual cycle itself produces small fluctuations, with levels slightly higher in the follicular phase when estrogen is rising. These fluctuations are small relative to reference range width and do not require cycle-timed collection unless you are tracking very narrow changes in a research context.

If you are trying to conceive and have irregular cycles, PCOS evaluation including IGFBP-3 and IGF-1 can add useful metabolic context. Low IGFBP-3 in this setting often correlates with the degree of insulin resistance, which directly affects ovarian androgen production and follicle development.

Pregnancy

IGFBP-3 rises substantially during pregnancy. Published data show mean IGFBP-3 levels in the third trimester reaching 5 to 8 mg/L, well above the non-pregnant adult range for many women. This rise is driven by placental GH, which stimulates IGF-1 and IGFBP-3 production and gradually suppresses pituitary GH secretion. Standard adult reference ranges are not applicable in pregnancy. If your clinician orders this test during pregnancy for any reason, make sure they are using pregnancy-specific normative data.

Postpartum

After delivery, placental GH disappears abruptly and pituitary GH resumes control of the axis. IGFBP-3 drops back toward pre-pregnancy levels within weeks. Women who experience postpartum hemorrhage severe enough to cause Sheehan syndrome may develop hypopituitarism, and IGFBP-3 will remain persistently low. This diagnosis is frequently missed for years because the symptoms, including fatigue, difficulty lactating, and loss of axillary and pubic hair, can be attributed to normal postpartum changes.

Perimenopause

This is the life stage where IGFBP-3 misinterpretation is most common. GH secretion declines with age and accelerates with estrogen loss. Symptoms of GH deficiency overlap almost perfectly with perimenopause: fatigue, poor sleep, body composition changes, cognitive fog, and reduced sense of well-being. Ordering IGFBP-3 alongside IGF-1 in symptomatic perimenopausal women who have a history of pituitary disease or radiation can be diagnostically useful, but ordering these tests in every perimenopausal woman without that history is unlikely to change management.

Post-Menopause

IGFBP-3 levels in post-menopausal women average about 30 to 40 percent lower than in premenopausal women of similar body composition, as shown in cross-sectional data from the EPIC-Norfolk cohort. Using a premenopausal reference range in this population will over-diagnose GH deficiency. Ask your lab which reference range they are applying.

How to Lower a High IGFBP-3

If acromegaly is the cause, treatment targets GH excess directly: transsphenoidal pituitary surgery is first-line, followed by somatostatin analogs (octreotide LAR or lanreotide) or pegvisomant if surgery does not achieve remission. The Endocrine Society acromegaly guidelines define biochemical control as IGF-1 within the age-adjusted reference range, with IGFBP-3 normalizing in parallel.

Outside of GH excess, physiologically elevated IGFBP-3 (puberty, pregnancy) does not require treatment.

How to Raise a Low IGFBP-3

Raising IGFBP-3 requires addressing the root cause. Here is a practical framework by underlying mechanism:

If the cause is insulin resistance (common in PCOS): Reducing fasting insulin through dietary carbohydrate reduction, aerobic exercise, and where indicated, metformin or GLP-1 receptor agonist therapy, will raise IGFBP-3 toward normal. This is not trivial: a 12-week trial of lifestyle intervention in women with PCOS showed significant increases in IGFBP-3 alongside improvements in insulin sensitivity.

If the cause is GH deficiency: Recombinant human GH (somatropin) replacement raises IGFBP-3 and IGF-1. Doses in women typically start lower and are titrated upward based on IGF-1 response, with a target in the upper half of the age-adjusted reference range. Women on oral estrogen may need 25 to 50 percent higher doses than women on transdermal estrogen or no estrogen, per pharmacokinetic data reviewed by the Endocrine Society.

If the cause is hypothyroidism: Treating to a TSH below 2.5 mIU/L typically restores GH axis function and raises IGFBP-3 over 3 to 6 months.

If the cause is caloric restriction or eating disorder: Medical nutrition therapy and weight restoration are necessary. IGFBP-3 is exquisitely sensitive to protein intake; women consuming below 0.8 g/kg/day of protein may show lower values that respond to dietary correction.

Pregnancy and Lactation: Special Considerations

IGFBP-3 is not a drug, so the pregnancy and lactation considerations here are about test interpretation, not drug safety.

In pregnancy: As noted above, IGFBP-3 rises progressively through each trimester. Do not use non-pregnant reference ranges. If acromegaly is suspected during pregnancy, the standard GH suppression test is not interpretable because placental GH is constitutively secreted and cannot be suppressed by glucose. IGF-1 and IGFBP-3 remain elevated throughout pregnancy even in normal women. This makes diagnosing or monitoring GH axis disorders during pregnancy particularly difficult, and management should involve a specialist in pituitary disease and a maternal-fetal medicine clinician.

Acromegaly treatment with somatostatin analogs is generally discontinued in pregnancy. Pegvisomant data in pregnancy are very limited. The European Journal of Endocrinology and ACOG both note that surveillance by a pituitary specialist throughout pregnancy is essential when a patient has known GH-secreting adenoma.

Postpartum and lactation: GH replacement (somatropin) is classified by the FDA as Pregnancy Category C and has limited human lactation data. LactMed, maintained by the NIH, notes that GH is a large protein unlikely to transfer to milk in clinically significant amounts, but formal lactation studies are absent. Clinicians generally pause GH replacement during lactation if the indication is not urgent, then restart afterward.

Contraception relevance: Women with acromegaly on somatostatin analogs should be aware that these drugs do not impair contraception, but uncontrolled GH excess itself can impair ovulation. Surgical or medical control of acromegaly has been associated with restoration of menstrual cyclicity, which can mean unintended conception in women who assumed their infertility was permanent. Effective contraception should be discussed before starting treatment.

Who Should Get This Test and Who Should Not

Good Candidates for IGFBP-3 Testing

• Women with symptoms of acromegaly: enlarging hands or feet, coarsening facial features, new snoring, excessive sweating, joint pain, carpal tunnel, new skin tags
• Women with confirmed or suspected hypopituitarism, particularly after Sheehan syndrome, pituitary surgery, or cranial irradiation
• Children being evaluated for short stature or growth failure alongside pediatric endocrinology
• Women with known pituitary adenoma on surveillance
• Women on GH replacement therapy (to monitor response)
• Women with borderline-low IGF-1 where a second marker would strengthen the diagnostic picture

Women Who Probably Do Not Need This Test

• Perimenopausal women with fatigue and body composition changes but no pituitary history (IGFBP-3 will likely be low-normal and will not change management)
• Women seeking cancer risk screening (not validated for this use)
• Women with PCOS who already have a clear metabolic picture from other markers
• Women with general wellness or anti-aging goals (low IGFBP-3 in this context is not an indication for GH therapy, which is not approved for age-related decline in healthy adults)

Evidence Gaps Affecting Women Specifically

Women have been under-represented in GH axis research. Most of the foundational pharmacokinetic studies of GH replacement used male-predominant cohorts, and reference ranges for IGFBP-3 in many laboratory systems were originally derived from datasets that included fewer women, particularly post-menopausal women. A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism noted that sex-specific normative data for IGF-1 and IGFBP-3 remain inconsistent across assay platforms and called for standardized sex-stratified reference intervals. Until that standardization occurs, always confirm that your lab is using a sex- and age-matched reference range, and treat borderline results with clinical judgment rather than treating the number in isolation.